Yukin Therapeutics
Monovalent degraders for the treatment of cancer and inflammatory diseases
Our mission is to develop small molecules targeting the difficult-to-drug NIK kinase for the treatment of human diseases involving NIK overexpression. The monovalent degraders designed by Yukin therapeutics overcome the development challenges posed by classic NIK kinase inhibitor activity. Our company’s main focus is oncology, however, inflammatory diseases will constitute a second arm currently under development.
